FCM
RANI icon

Farallon Capital Management’s Rani Therapeutics RANI Stock Holding History

Farallon Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.3K Hold
78,000
– – ﹤0.01% 167
2025
Q4 		$105K Buy
+78,000
New +$118K ﹤0.01% 144

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Farallon Capital Management's RANI Position: Q1 2026 in Review

Farallon Capital Management held its Rani Therapeutics (RANI) position steady in Q1 2026 at 78,000 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #167.

Farallon Capital Management first reported a position in RANI in Q4 2025 and has held it in 2 quarters since. The position peaked at $105K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Farallon Capital Management held 78,000 shares of Rani Therapeutics worth $57.3K as of Q1 2026.
  • Farallon Capital Management left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #167 holding.
  • Farallon Capital Management first reported a position in Rani Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Farallon Capital Management's Rani Therapeutics position peaked at $105K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.